IDEAYA Biosciences Grants Stock Options to New Employees Under Nasdaq Rule 5635(c)(4) to Enhance Talent Pool

IDEAYA Biosciences Expands Talent Pool with Strategic Stock Options Grant

On April 25, 2025, IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a company dedicated to precision medicine in oncology, made an important announcement regarding the enhancement of its workforce. The company stated that on April 24, 2025, its Board of Directors' Compensation Committee approved the granting of non-qualified stock options aimed at attracting fresh talent. A total of 185,400 shares of common stock were awarded to four newly appointed employees as part of this incentive.

This grant was executed under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (referred to as the 2023 Inducement Plan). This plan specifically caters to individuals who were not employed by IDEAYA prior to their acceptance of a position, as delineated by Nasdaq Listing Rule 5635(c)(4). This strategic move not only reflects IDEAYA’s commitment to building a strong team but also its adherence to established regulations in public company governance.

The stock options granted come with an exercise price set at $19.07 per share, matching the closing price of IDEAYA's common stock on the Nasdaq Global Select Market on the day the options were issued. Employees can benefit from these options over a ten-year term, with vesting scheduled over a span of four years. Initially, 25% of the granted options vest on the first anniversary followed by monthly installments for the remaining 75% in the subsequent three years. Importantly, continuous employment at IDEAYA on each vesting anniversary is required for employees to access the granted options.

Such inducements are crucial for a company like IDEAYA, which is deeply invested in the discovery and development of targeted therapies aimed at addressing unique patient populations designated through molecular diagnostics. IDEAYA employs advanced methodologies in identifying and validating translational biomarkers, ensuring that its precision medicine targets are both innovative and disruptive in the oncology space.

IDEAYA’s strategy leans heavily on the emerging field of synthetic lethality, representing an exciting frontier in precision medicine. By leveraging its early research capabilities and drug discovery processes, IDEAYA is setting itself apart within the competitive landscape of oncology-focused biopharmaceutical companies. This latest stock options grant is a key step toward strengthening IDEAYA’s commitment to integrating top-tier professionals whose skills align with the company’s ambitious research goals.

As the healthcare ecosystem continues to evolve, IDEAYA Biosciences positions itself at the forefront by not only attracting experienced professionals but also nurturing a collaborative and innovative workplace culture that focuses on significant contributions to patient care through groundbreaking therapies. With these new stock options, IDEAYA aims to solidify its current workforce while remaining agile in adapting to the rapidly changing demands of the biotech industry.

IDEAYA Biosciences remains dedicated to fulfilling its mission through strategic workforce development while continuing to foster an environment that encourages innovation and excellence in the field of oncology.

For more details regarding IDEAYA Biosciences and its ongoing initiatives, interested parties may contact Andres Ruiz Briseno, Chief Accounting Officer, through the provided media contact channels or follow updates on the company’s official communications.